Global Phase III Clinical Trial Research on Recombinant COVID-19 Vaccine (Sf9cells) in Nepal

Global Phase III Clinical Trial Research on Recombinant COVID-19 Vaccine (Sf9cells) in Nepal

Since emerging in December 2019, the Coronavirus Disease 2019(COVID-19) outbreak was deemed a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 30 January 2020. The COVID-19 pandemic has brought heavy economic pressure, medical burden, and severe harm to people's lives and health. Currently, about 250 study vaccines against SARS-CoV-2 are in development worldwide. SOLID Nepal in partnership with MSR (Beijing) Pharmaceutical Consulting Co., Ltd. is conducting a phase III clinical trial on recombinant COVID-19 vaccine (sf9cells). This study is being conducted across four countries: Philippines, Indonesia, Kenya and Nepal. The objective of the study is to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older. Till now 1199 participants have received all three doses of (sf9cells) vaccine and are being constantly follow up. So far, the research is being implemented smoothly and through this research SOLID Nepal has developed its institutional capacity to undertake similar projects in upcoming days.